J. Newton

SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.

H. Sarau, G. Poste, J. Gleason, 1987, Biochemical pharmacology.

Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.

H. Sarau, J. Lee, P. Bender, 1991, Biochemical pharmacology.

Pharmacology of the pyrroloimidazole, SK&F 105809--II. Antiinflammatory activity and inhibition of mediator production in vivo.

J. Lee, N. Hanna, D. Griswold, 1991, Biochemical pharmacology.

Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.

J. Adams, R. Garigipati, L. A. Yodis, 1996, Journal of medicinal chemistry.